Result of Retail Offer
CRISM Therapeutics Corporation has successfully raised gross proceeds of £59,610 through a retail offer of 662,332 shares at 9 pence per share. These funds, combined with those from a prior placing, will support the company's MHRA-approved Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients, with patient dosing expected in Q1 2026. The new Retail Offer Shares will be admitted to trading on the London Stock Exchange around December 16, 2025, bringing the total issued share capital to 51,735,266 ordinary shares.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Result of Retail Offer
Further to the announcement by the Company in respect of the Retail Offer dated 10 December 2025, CRISM Therapeutics Corporation announces that, following the closing of the Retail Offer on the BookBuild platform today at 12.00 p.m., the Company has raised gross proceeds of £59,610 (the "Retail Offer") by way of a subscription of 662,332 Retail Offer Shares at the Issue Price of 9 pence per share.
The proceeds of the Retail Offer together with the Placing announced on 10 December 2025 (together the "Proceeds"), will enable the Company to progress its MHRA approved, Phase 2 open-label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma, with first patients expected to be dosed in Q1 2026.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the Retail Offer Shares ("Admission"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 16 December 2025, or such later date as may be agreed between the Company and SP Angel. The Retail Offer Shares will rank pari passu with the Company's existing ordinary shares.
Following the issue of the Retail Offer Shares, the total issued share capital of the Company will consist of 51,735,266 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,735,266 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Other than where defined, capitalised terms used in this Announcement have the meanings given to them in the announcements of 10 December 2025.
The Company's LEI is 213800XFW6MKVCHHPW88.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.